144 related articles for article (PubMed ID: 33219473)
1. Clinical study on empirical and diagnostic-driven (pre-emptive) therapy of voriconazole in severe aplastic anaemia patients with invasive fungal disease after intensive immunosuppressive therapy.
Wu Y; Yan L; Wang H; Liu H; Xing L; Fu R; Shao Z
Eur J Clin Microbiol Infect Dis; 2021 May; 40(5):949-954. PubMed ID: 33219473
[TBL] [Abstract][Full Text] [Related]
2. [Value of the Diagnostic-Driven Therapy with Voriconazole in Patients with Hematological Disorders Complicated by Invasive Fungal Disease].
Su PX; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1272-1276. PubMed ID: 35981397
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China.
Xu XH; Zhang L; Cao XX; Li J; Zhang W; Zhu TN; Cai HC; Chen M; Han X; Yang C; Han B; Zhang Y; Zhuang JL; Zhou DB; Duan MH
J Infect Chemother; 2017 Jun; 23(6):360-367. PubMed ID: 28341518
[TBL] [Abstract][Full Text] [Related]
4. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
[No Abstract] [Full Text] [Related]
5. Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial.
Santolaya ME; Alvarez AM; Acuña M; Avilés CL; Salgado C; Tordecilla J; Varas M; Venegas M; Villarroel M; Zubieta M; Farfán M; de la Maza V; Vergara A; Valenzuela R; Torres JP
J Antimicrob Chemother; 2018 Oct; 73(10):2860-2866. PubMed ID: 30010931
[TBL] [Abstract][Full Text] [Related]
6. Empirical antifungal treatment for diagnosed and undiagnosed invasive fungal disease in patients with hematologic malignancies.
Deng Q; Lv HR; Lin XM; Zhao MF; Geng L; Li YM
Curr Med Res Opin; 2018 Jul; 34(7):1209-1216. PubMed ID: 28956459
[TBL] [Abstract][Full Text] [Related]
7. Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis.
Chen L; Wang T; Wang Y; Yang Q; Xie J; Li Y; Lei J; Wang X; Xing J; Dong Y; Dong H
Fundam Clin Pharmacol; 2016 Oct; 30(5):459-65. PubMed ID: 27341147
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
9. Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R; Montesinos P; Boluda B; Lorenzo I; Martínez-Cuadrón D; Salavert M; Pemán J; Calvillo P; Cano I; Acuña E; Villalba A; Piñana JL; Sanz J; Solves P; Senent L; Vicente A; Sempere A; Cervera J; Barragán E; Jarque I; Torres A; Sanz MA; Sanz GF
Ann Hematol; 2019 Sep; 98(9):2081-2088. PubMed ID: 31240471
[TBL] [Abstract][Full Text] [Related]
10. [Clinical investigation of reduced-dose voriconazole on primary prevention in invasive fungal disease after allogeneic hematopoietic stem cell transplantation].
Qiu Z; Ren H; Cen X; Ou J; Xu W; Wang M; Wang L; Dong Y; Li Y; Liu W; Sun Y; Liang Z; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):577-80. PubMed ID: 25052595
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study.
Tang L; Yang XF; Qiao M; Zhang L; Tang XW; Qiu HY; Wu DP; Sun AN
J Mycol Med; 2018 Jun; 28(2):379-383. PubMed ID: 29673771
[TBL] [Abstract][Full Text] [Related]
12. Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies.
Perreault S; McManus D; Anderson A; Lin T; Ruggero M; Topal JE
J Oncol Pharm Pract; 2019 Sep; 25(6):1305-1311. PubMed ID: 29996736
[TBL] [Abstract][Full Text] [Related]
13. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
[TBL] [Abstract][Full Text] [Related]
14. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.
Maertens J; Selleslag D; Heinz WJ; Saulay M; Rahav G; Giladi M; Aoun M; Kovanda L; Kaufhold A; Engelhardt M; Cornely OA; Herbrecht R; Ullmann AJ
Mycoses; 2018 Nov; 61(11):868-876. PubMed ID: 30035825
[TBL] [Abstract][Full Text] [Related]
16. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
Qiu KY; Liao XY; Fang JP; Xu HG; Li Y; Huang K; Zhou DH
Transpl Infect Dis; 2019 Jun; 21(3):e13066. PubMed ID: 30859662
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
[TBL] [Abstract][Full Text] [Related]
18. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.
Trubiano JA; Crowe A; Worth LJ; Thursky KA; Slavin MA
J Antimicrob Chemother; 2015 Apr; 70(4):1161-5. PubMed ID: 25558073
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia.
Tu S; Zhang K; Wang N; Chu J; Yang L; Xie Z
Sci Rep; 2023 Nov; 13(1):18789. PubMed ID: 37914820
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis.
Rosanova MT; Bes D; Serrano Aguilar P; Sberna N; Lede R
Infect Dis (Lond); 2018 Jul; 50(7):489-494. PubMed ID: 29262742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
